Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...

Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, ...

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

The following is a summary of “Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab,” published in the April 2025 issue of Journal of ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...

Lyell Immunopharma (LYEL) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy, RMAT, ...

This study uncovers dynamic immune adaptations during pregnancy through single-cell RNA sequencing of peripheral blood ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of 113 healthcare workers in Catalonia who were followed during three years. The ...